Business
Endonovo Therapeutics Inc. (ENDV) Announces it has filed a Regulation A+ Financing & Retained Dalmore Group to Provide Operations & Compliance
Endonovo Therapeutics Inc. (ENDV) Announces it has filed a Regulation A+ Financing & Retained Dalmore Group to Provide Operations & Compliance.
About this update from Endonovo Therapeutics, Inc.
[{"type":"text","content":"\n Los Angeles, CA, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Endonovo Therapeutics Inc. (OTC-ENDV) an Innovative Medical Devices developer and distributor is pleased to announce it has filed a Regulation A+ financing for expansion of their operations and has retained Dalmore Group (“Dalmore”), a veteran industry leading broker-dealer to provide operations and compliance services in the completion of this Regulation A+ and its anticipated subsequent Reg A+ offering. The financing proceeds for this Reg A+ are planned to be used to repay its senior secured Note, for research and development and working capital. Click here to see and review Endonovo’s Regulation A+ filing and to receive press releases and SEC filings via email when they occur. In retaining Dalmore Group, Endonovo has positioned their Reg A+ Financing to capitalize on the strengths and successes that Dalmore Group has established as being an industry leading broker-dealer in Reg A+ Financing services. Dalmore Group, with more than 16 years’ experience as a full-service investment bank with deep institutional, private equity, venture capital and family office relationships in multiple financial markets, is considered the US industry leading broker-dealer for Reg A+ offerings having onboarded over 175 Reg A+ issuers since 2019. As a consultant Dalmore Group offers Endonovo marketing guidance and experienced securities regulation compliance review as well as a wide variety of financial funding alternatives and structures. Dalmore Group is a registered broker-dealer providing services in the equity and debt securities market, including offerings conducted via exemptions from registration with the SEC such as Reg D 506(b), 506(c), Reg CF and Reg A+ offerings. Dalmore clients include a mix of private and publicly listed companies in both the US and Canada. Dalmore services include strategic partnerships with industry experts in marketing and PR, distribution and syndication-partnerships with multiple Reg A+ marketplace platform distribution partners, and secondary trading solutions for their Reg A+ issuers, thereby enabling issuers to offer ongoing liquidity solutions to their investors. Etan Butler, Chairman of Dalmore Group states, “having onboarded over 175 Reg A+ issuers since 2019, we are now seeing a rapid increase of OTC companies utilizing th...